Novo Nordisk A/S (CPH:NOVO.B)
305.30
-4.05 (-1.31%)
Dec 17, 2025, 10:45 AM CET
Novo Nordisk Revenue
Novo Nordisk had revenue of 74.98B DKK in the quarter ending September 30, 2025, with 5.14% growth. This brings the company's revenue in the last twelve months to 315.60B, up 16.64% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
315.60B
Revenue Growth
+16.64%
P/S Ratio
4.36
Revenue / Employee
4.02M
Employees
77,349
Market Cap
1.37T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | 122.02B | 10.19B | 9.11% |
| Dec 31, 2018 | 111.83B | 135.00M | 0.12% |
| Dec 31, 2017 | 111.70B | -84.00M | -0.08% |
| Dec 31, 2016 | 111.78B | 3.85B | 3.57% |
| Dec 31, 2015 | 107.93B | 19.12B | 21.53% |
| Dec 31, 2014 | 88.81B | 5.23B | 6.26% |
| Dec 31, 2013 | 83.57B | 5.55B | 7.11% |
| Dec 31, 2012 | 78.03B | 11.68B | 17.60% |
| Dec 31, 2011 | 66.35B | 5.57B | 9.16% |
| Dec 31, 2010 | 60.78B | 9.70B | 18.99% |
| Dec 31, 2009 | 51.08B | 5.53B | 12.13% |
| Dec 31, 2008 | 45.55B | 3.72B | 8.90% |
| Dec 31, 2007 | 41.83B | 3.09B | 7.97% |
| Dec 31, 2006 | 38.74B | 4.98B | 14.76% |
| Dec 31, 2005 | 33.76B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Coloplast | 27.87B |
| Genmab | 24.48B |
| H. Lundbeck | 24.08B |
| Demant | 22.59B |
| GN Store Nord | 17.12B |
| Zealand Pharma | 9.16B |
| Bavarian Nordic | 6.89B |
| ALK-Abelló | 6.08B |
Novo Nordisk News
- 14 hours ago - Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly - CNBC
- 21 hours ago - Novo Nordisk Loses Momentum As Eli Lilly Pulls Ahead In Weight-Loss Wars - Benzinga
- 21 hours ago - Novo Nordisk Loses Momentum As Eli Lilly Pulls Ahead In Weight-Loss Wars - Benzinga
- 1 day ago - CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval - Nasdaq
- 2 days ago - 2 Predictions for Novo Nordisk in 2026 - The Motley Fool
- 3 days ago - Ozempic Enters India: Diabetes Drug, Not A Miracle Fix, Novo Nordisk MD To NDTV - NDTV
- 4 days ago - European Regulator Backs Approval Of Novo Nordisk High-Dose Wegovy - Benzinga
- 4 days ago - NVO Down 42% Year to Date: Is This an Indication to Sell the Stock? - Nasdaq